Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma

Clinical and Experimental Metastasis

Volumn 21, Issue 4, 2004, Pages 321-329

  Suzuki, Hideo ^a   Shoda, Junichi ^a   Kawamoto, Toru ^a   Shinozaki, Eiji ^a   Miyahara, Naoki ^a   Hotta, Souichi ^b   Iizuka, Yasushi ^c   Nakahara, Akira ^a   Tanaka, Naomi ^a   Yanaka, Akinori ^a   Irimura, Tatsuro ^d  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Hitachi   (Japan)

^c Mitsukaido shi Ibaraki Japan   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

in situ hybridization; mAb MY.1E12; MUC; MUC1; mucin core polypeptide; immunohistochemistry; postsurgical survival; tumor biology

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MY.1E12; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURVIVAL; COLON CARCINOMA; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CA-15-3 ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PERITONEAL NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 7244248864     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CLIN.0000046133.35133.cc     Document Type: Article

References (47)

1. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932; 35: 323-32.
2. Sugarbaker PH, Gunderson LL, Wittes RE. Colorectal cancer. In DeVita Jr VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 2nd edition. Philadelphia, Pennsylvania: JB Lippincott 1985; 795-884.
3. Eisenberg B, DeCosse JJ, Harford F et al. Carcinoma of the colon and rectum: The natural history reviewed in 1704 patients. Cancer 1982; 49: 1131-1.
4. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically resected rectal cancer. N Engl J Med 1985; 3/2: 1465-72.
5. Galandiuk S, Wieand HS, Moertel CG et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27-32.
6. Nicolson GL. Cancer metastasis. Organ colonization and cell surface properties of malignant cells. Biochem Biophys Acta 1982; 695: 113-76.
7. Irimura T, Reading CL. Surface properties of metastatic tumor cells. Cancer Bull 1987; 39: 132-41.
8. Matsushita Y, Cleary KR, Ota DM et al. Sialyl-dimetric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastasis. Lab Invest 1990; 63: 780-91.
9. Irimura T, Matsushita Y, Hoff SD et al. Ectopic expression of mucins in colorectal cancer metastasis. Semin Cancer Biol 1991; 2: 129-39.
10. Ponta H, Sleeman J, Herrlich P. Tumor metastasis formation: Cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochem Biophys Acta 1994; 1198: 1-10.
11. Hilkens J, Ligtenberg MJ, Vos HL et al. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992; 17: 359-63.
12. Nakamori S, Ota DM, Cleary KR et al. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 1994; 106: 353-61.
13. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286-93.
14. Ligtenberg MJ, Buijs F, Vos HL et al. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992; 52: 2318-234.
15. Hilkens J, Wesseling J, Vos HL et al. Episialin modulates cell-cell and cell-matrix adhesion, promotes invasion in matrigel and inhibits cytolysis by cytotoxic effector cells. In Preissner KT, Rosenblatt S, Kost C et al. (eds): Biology of Vitronectins and Their Receptors. Amsterdam: Excerpta Medica 1993; 193-200.
16. Yamamoto M, Bhavanandan VP, Nakamori S et al. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jpn J Cancer Res 1996; 87: 488-96.
17. Takeuchi H, Kato K Denda-Nagai K et al. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyla2- 3galactosylβ1-3N-acetylgalactosaminide linked to a distinct theonine residue in the MUC1 tandem repeat. J Immunol Meth 2002; 270: 199-209.
18. Higashi M, Yonezawa S, Ho JJL et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999; 30: 1347-55.
19. Yonezawa S, Sato E. Expression of mucin antigens in human cancer and its relationship with malignancy potential. Pathol Int 1997; 47: 813-40.
20. Yonezawa S, Taira M, Osako M et al. MUC1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int 1998; 48: 319-22.
21. Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer 1999; 80: 301-8.
22. Kawamoto T, Shoda J, Irimura T et al. Expression of MUC1 mucins in the subserosal layer correlates with post-surgical prognosis of pT2 carcinoma of the gallbladder. Clin Cancer Res 2001; 7: 1333-12.
23. Fleming ID, Cooper JS, Henson DE et al (eds): AJCC Cancer Staging Manual, 5th ed. Philadelphia, Pennsylvania: Lippincott-Raven 1997.
24. Hamada Y, Yamamura M, Hioki K et al. Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Correlation with plasma carcinoembryonic antigen levels. Cancer 1985; 55: 136-41.
25. Sasaki M, Nakanuma Y, Kim YS. Expression of apomucins in the intrahepatic biliary tree in hepatolithiasis differs from that in normal liver and extrahepatic biliary obstruction. Hepatology 1998; 27: 46-53.
26. Hiraga Y, Tanaka S, Haruma K et al. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55: 307-19.
27. Aoki R, Tanaka S, Harama K et al. MUC1 expression as a predictor of the curative endoscopie treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum 1998; 41: 1262-72.
28. Matsushita Y, Cleary KR, Ota DM et al. Sialyl-dimetric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastasis. Lab Invest 1990; 63: 780-91.
29. Irimura T, Ota DM, Cleary KR. Ulex europeus agglutinin I-reactive high molecular weight glycoproteins of adenocarcinoma of distal colon and rectum and their possible relationships with metastatic potential. Cancer Res 1987; 47: 881-9.
30. Irimura T, Carlson DA, Price J et al. Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. Cancer Res 1989; 48: 2353-60.
31. X antigen in liver metastasis of human colorectal carcinoma. Cancer Res 1989; 49: 6883-8.
32. Kim YS, Gum Jr J, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj J 1996: 13: 693-707.
33. Lesuffleuer T, Zweibaum A, Real FX. Mucins in normal and neoplastic human gastrointestinal tissues. Crit Rev Oncol Hematol 1994; 17: 153-80.
34. Dobrossy L, Pavelic ZP, Bernacki RJ. A correlation between cell surface sialyltransferase, sialic acid, and glycosidase activities and the implantability of B16 murine melanoma. Cancer Res 1981; 41: 2262-6.
35. Passaniti A, Hart GW. Cell surface sialylation and tumor metastasis. J Biol Chem 1988; 263: 591-7603.
36. Kawamoto T, Shoda J, Miyahara N et al. Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metast 2004; 21: 353-62 (this issue).
37. Brabletz T, Jung A, Hermann K et al. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 1998; 194: 701-4.
38. Li Y, Ren J, Yu W et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 2001; 276: 35239-12.
39. Schroeder JA, Thompson MC, Gardner MM et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 13057-64.
40. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
41. Birchmeier W, Behrens J. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochem Biophys Acta 1994; 1198: 11-26.
42. Irimura T, McIsaac AM, Carlson DA et al. Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein produced by human colon carcinoma cells. Cancer Res 1990; 50: 3331-8.
43. Dohi DF, Sutton RC, Frazier ML et al. Regulation of sialomucin production in colon carcinoma cells. J Biol Chem 1993; 268: 10133-8.
44. Shirotani K, Taylor-Papadimitriou J, Gendler SJ et al. Transcriptional regulation of the MUC1 mucin gene in colon carcinoma cells by a soluble factor. Identification of a regulatory element. J Biol Chem 1994; 269: 15030-5.
45. Zhang K, Baeckstrom D, Brevinge H et al. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J Cell Biochem 1996; 60: 538-19.
46. Treon SP, Maimonis P, Bua D et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple melanoma. Blood 2000; 96: 3147-53.
47. Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-a converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 2003; 278: 3386-94.